APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status
John Quinn(London Cancer), Kwee Yong(CRUK Lung Cancer Centre of Excellence)
Cited by 64
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Guidelines for the diagnosis and management of multiple myeloma 2011
|British Journal of Haematology|2011|305
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
|The Lancet Oncology|2019|160
Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment
|British Journal of Haematology|2017|64